NCT06890702 Clinical Evaluation of New Biomarkers for Ischemic Cerebrovascular Disease
| NCT ID | NCT06890702 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tongji Hospital |
| Condition | Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 7,000 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2035-12-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 7,000 participants in total. It began in 2025-01-01 with a primary completion date of 2035-12-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this single-center prospective observational study is to identify and evaluate new biomarkers for ischemic cerebrovascular disease (ICVD) to aid in early diagnosis, individualized treatment planning, and prognosis prediction in affected patients. The main questions it aims to answer are: Can specific biomarkers help in identifying high-risk individuals before disease onset? Can these biomarkers predict disease progression and treatment response? Researchers will compare patients diagnosed with ICVD and healthy controls from a medical check-up center to assess differences in biomarker expression and their clinical significance. Participants will: Provide blood, cerebrospinal fluid, urine, and stool samples for biomarker analysis. Undergo clinical imaging (CT, MRI, PET-CT) and functional assessments. Be followed up at 3, 6, 12, 24, 36, and 48 months for clinical outcomes and biomarker changes. This study aims to develop a comprehensive biomarker-based prediction model to enhance the diagnosis and management of ischemic cerebrovascular disease.
Eligibility Criteria
Inclusion Criteria: * Ischemic cerebrovascular disease has been proved by clinical symptoms and imaging examinations,including transient ischemic attack, cerebral ischemic stroke, steal syndrome, chronic cerebral hypoperfusion, ect al. * sex and age-matched healthy individuals Exclusion Criteria: * Brain CT or MRI showing cerebral hemorrhage (excluded ischemic stroke with hemorrhage transformation) * With severe systemic disease, are expected to survive \< 3 months * Patients will not able to provide continuous follow-up information
Contact & Investigator
Dai-Shi Tian
PRINCIPAL INVESTIGATOR
Tongji Hospital
Frequently Asked Questions
Who can join the NCT06890702 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06890702 currently recruiting?
Yes, NCT06890702 is actively recruiting participants. Contact the research team at zhouluoqi@tjh.tjmu.edu.cn for enrollment information.
Where is the NCT06890702 trial being conducted?
This trial is being conducted at Wuhan, China, Wuhan, China.
Who is sponsoring the NCT06890702 clinical trial?
NCT06890702 is sponsored by Tongji Hospital. The principal investigator is Dai-Shi Tian at Tongji Hospital. The trial plans to enroll 7,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.